Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Post by Steveminon Mar 30, 2021 4:59pm
178 Views
Post# 32908174

Adams needs to be replaced

Adams needs to be replaced
It's been stated so many times that now maybe some may finally choose to believe that Adams has ZERO interest in creating shareholder value. His whole business plan is to keep repeating the same mantra over and over claiming they can do things that clearly the market doesn't believe they can do while he continues to kick the can down the road to ensure he and all
his cronies that he hired continue to get a paycheck while the competion passes them by.
 
If things were as "transformational and exciting" as he's stated they are (for the last two years), why the need to continually do cap raises with terrible terms and at suppressed sp levels causing endless dilution?
Why do insiders own virtually zero stock in the company?
Why do investor emails and calls never get answered?
 
As of close of market today, Inmed's stock price is $3.13 US or $0.095/share prior to the reverse split. When Adams took over the sp was $0.074/share US (adjusted for the reverse split). A 22% decline! I mean really??
Obviously neither the market nor any legitimate financing company/partner/investor believes a thing that Adams has said.
 
Basically all of the pumpers have admittedly sold and moved on - which, by the way, is exactly what Adams wants. He wants all of the "old, long term" investors to sell and move on so a new crop of suckers can come and buy into his garbage.
 
I've invested for decades and never have I experienced such lack of transparency and shareholder communication as I have with Eric Adams. It is truly disgraceful.

Sorry, but its time for a new CEO to steer the company in the correct direction.
<< Previous
Bullboard Posts
Next >>